• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Corporate News

 Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors
0
By Nascent Biotech
In Corporate News
Posted April 14, 2016

Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors

Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & [...]

READ MORE
 Nascent Biotech, Inc. Announces an Agreement Reducing Its Liabilities By $1.4 Million
0
By Nascent Biotech
In Corporate News
Posted September 21, 2015

Nascent Biotech, Inc. Announces an Agreement Reducing Its Liabilities By $1.4 Million

San Diego, CA September 21, 2015 – Nascent Biotech, Inc. (“Nascent” or “the Company”) (PINK.BB: NBIO), reached an agreement with the licensor whereby the licensor will receive cash payments [...]

READ MORE
 Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt
0
By Nascent Biotech
In Corporate News, News
Posted September 17, 2015

Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt

San Diego, CA September 17, 2015 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (PINK.BB: NBIO) is pleased to announce that it has retired the $ 60,000 convertible debenture effective [...]

READ MORE
 Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment
0
By Nascent Biotech
In Corporate News, Science News
Posted August 13, 2015

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO). Since March of 2014 Nascent has raised $2.1 million which has been used to advance the [...]

READ MORE
 Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted June 18, 2015

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its [...]

READ MORE
 Nascent Biotech Announces Orphan Drug Designation for Brain Cancer
0
By Nascent Biotech
In Corporate News, Press Releases
Posted April 9, 2015

Nascent Biotech Announces Orphan Drug Designation for Brain Cancer

San Diego, CA, April 9th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the [...]

READ MORE
 Nascent Biotech Announces $225,000 NIH Grant Award in Conjunction with Mapp Biopharmaceutical
0
By Nascent Biotech
In Corporate News, Press Releases
Posted February 26, 2015

Nascent Biotech Announces $225,000 NIH Grant Award in Conjunction with Mapp Biopharmaceutical

San Diego, CA, February 26th, 2015 – Nascent Biotech, Inc. (OTC: NBIO) and Mapp Biopharmaceutical announced today they have been awarded a $225,000 Small Business Innovative Research (SBIR) [...]

READ MORE
 Nascent Biotech Inc. Raises $1.2 Million in Initial Funding
0
By Nascent Biotech
In Corporate News, Press Releases
Posted February 19, 2015

Nascent Biotech Inc. Raises $1.2 Million in Initial Funding

San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million. Management raised [...]

READ MORE
1 2 3 4 5
page 1 of 5
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.